Distribution of 13 truncating mutations in the neurofibromatosis 1 gene.

Neurofibromatosis 1 (NF1) is a common genetic disorder characterized by abnormalities of tissues derived from the neural crest. To define germ-line mutations in the NF1 gene, we studied 20 patients with familial or sporadic cases of NF1 diagnosed clinically and one patient with only café-au-lait spots and no other diagnostic criteria. A protein truncation assay identified abnormal polypeptides synthesized in vitro from five RT-PCR products that represented the entire NF1 coding region. Truncated polypeptides were observed in 14 individuals. The mutations responsible for the generation of abnormal polypeptides were characterized by DNA sequencing. Thirteen previously unpublished mutations were characterized in the 14 individuals. The mutation 2027insC was observed in two unrelated individuals; the other 12 mutations were unique. The sequence changes included seven nonsense and four frameshift mutations that created premature translation termination signals, and two large in-frame deletions that led to the synthesis of truncated polypeptides. One of the mutations was found in the child with a single clinical diagnostic criterion, providing her with a presumptive diagnosis of NF1. Our results confirm that truncating mutations are frequent in both familial and sporadic NF1 cases. The identification of mutations in 14 of 21 individuals studied (67%) suggests that the use of protein truncation assays will rapidly accelerate the rate of identification of NF1 mutations. Because we scanned the entire NF1 coding region in each individual, the distribution of NF1 truncating mutations was discerned for the first time. The mutations were relatively evenly distributed throughout the coding region with no evidence for clustering.

[1]  T. Yoshimoto,et al.  Brain tumors predominantly express the neurofibromatosis type 1 gene transcripts containing the 63 base insert in the region coding for GTPase activating protein-related domain. , 1991, Biochemical and biophysical research communications.

[2]  B. Brownstein,et al.  Type 1 neurofibromatosis gene: identification of a large transcript disrupted in three NF1 patients. , 1990, Science.

[3]  M. Cayouette,et al.  Mutational analysis of patients with neurofibromatosis, type 1 (NF1) and malignant myeloid disorders using a protein truncation assay. , 1995 .

[4]  David Valle,et al.  The skipping of constitutive exons in vivo induced by nonsense mutations , 1993, Science.

[5]  U. K. Laemmli,et al.  Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4 , 1970, Nature.

[6]  A. Matynia,et al.  Molecular analysis of Hurler syndrome in Druze and Muslim Arab patients in Israel: multiple allelic mutations of the IDUA gene in a small geographic area. , 1993, American journal of human genetics.

[7]  K. Kinzler,et al.  Molecular diagnosis of familial adenomatous polyposis. , 1993, The New England journal of medicine.

[8]  P. O'Connell,et al.  Genomic organization of the neurofibromatosis 1 gene (NF1). , 1995, Genomics.

[9]  D. Louis,et al.  Mutational analysis of patients with neurofibromatosis 2. , 1994, American journal of human genetics.

[10]  M. Skolnick,et al.  The Genetic Aspects of Neurofibromatosis a , 1986, Annals of the New York Academy of Sciences.

[11]  A. Harris,et al.  The stop mutation R553X in the CFTR gene results in exon skipping. , 1994, Genomics.

[12]  F. Tamanoi,et al.  The catalytic domain of the neurofibromatosis type 1 gene product stimulates ras GTPase and complements ira mutants of S. cerevisiae , 1990, Cell.

[13]  Simeon I. Taylor,et al.  A nonsense mutation causing decreased levels of insulin receptor mRNA: detection by a simplified technique for direct sequencing of genomic DNA amplified by the polymerase chain reaction. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[14]  Shirley A. Miller,et al.  A simple salting out procedure for extracting DNA from human nucleated cells. , 1988, Nucleic acids research.

[15]  H. Dietz,et al.  Maintenance of an open reading frame as an additional level of scrutiny during splice site selection , 1994, Nature Genetics.

[16]  M. Wigler,et al.  The NF1 locus encodes a protein functionally related to mammalian GAP and yeast IRA proteins , 1990, Cell.

[17]  R. Sinden,et al.  DNA structure, mutations, and human genetic disease. , 1992, Current opinion in biotechnology.

[18]  F. Collins,et al.  Aberrant regulation of ras proteins in malignant tumour cells from type 1 neurofibromatosis patients , 1992, Nature.

[19]  S. Baserga,et al.  Beta-globin nonsense mutation: deficient accumulation of mRNA occurs despite normal cytoplasmic stability. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[20]  N. Copeland,et al.  Sequence homology shared by neurofibromatosis type-1 gene and IRA-1 and IRA-2 negative regulators of the RAS cyclic AMP pathway , 1990, Nature.

[21]  J. D. den Dunnen,et al.  Protein truncation test (PTT) for rapid detection of translation-terminating mutations. , 1993, Human molecular genetics.

[22]  D. Lowy,et al.  Abnormal regulation of mammalian p21ras contributes to malignant tumor growth in von Recklinghausen (type 1) neurofibromatosis , 1992, Cell.

[23]  M. Inouye,et al.  Frameshift mutations and the genetic code. This paper is dedicated to Professor Theodosius Dobzhansky on the occasion of his 66th birthday. , 1966, Cold Spring Harbor symposia on quantitative biology.

[24]  A. Hamosh,et al.  Severe deficiency of cystic fibrosis transmembrane conductance regulator messenger RNA carrying nonsense mutations R553X and W1316X in respiratory epithelial cells of patients with cystic fibrosis. , 1991, The Journal of clinical investigation.

[25]  F. Giannelli,et al.  Analysis of factor VIII mRNA reveals defects in everyone of 28 haemophilia A patients. , 1993, Human molecular genetics.

[26]  M. Skolnick,et al.  A collaborative survey of 80 mutations in the BRCA1 breast and ovarian cancer susceptibility gene. Implications for presymptomatic testing and screening. , 1995, JAMA.

[27]  M. Boguski,et al.  cDNA cloning of the type 1 neurofibromatosis gene: complete sequence of the NF1 gene product. , 1991, Genomics.

[28]  H. Saya,et al.  Differential expression of two types of the neurofibromatosis type 1 (NF1) gene transcripts related to neuronal differentiation. , 1991, Oncogene.

[29]  M. Lerman,et al.  Identification of intragenic mutations in the von Hippel-Lindau disease tumour suppressor gene and correlation with disease phenotype. , 1994, Human molecular genetics.

[30]  D. Shaw,et al.  Molecular basis of neurofibromatosis type 1 (NF1): Mutation analysis and polymorphisms in the NF1 gene , 1994, Human mutation.

[31]  R. Weleber,et al.  Nonsense-codon mutations of the ornithine aminotransferase gene with decreased levels of mutant mRNA in gyrate atrophy. , 1992, American journal of human genetics.

[32]  J. Sambrook,et al.  Molecular Cloning: A Laboratory Manual , 2001 .

[33]  P. O'Connell,et al.  Deletions and a translocation interrupt a cloned gene at the neurofibromatosis type 1 locus , 1990, Cell.

[34]  G. Sarkar,et al.  Access to a messenger RNA sequence or its protein product is not limited by tissue or species specificity. , 1989, Science.

[35]  Margaret Robertson,et al.  The neurofibromatosis type 1 gene encodes a protein related to GAP , 1990, Cell.

[36]  P. O'Connell,et al.  A major segment of the neurofibromatosis type 1 gene: cDNA sequence, genomic structure, and point mutations , 1990, Cell.

[37]  P. Chomczyński,et al.  Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. , 1987, Analytical biochemistry.

[38]  R. Heim,et al.  Screening for truncated NF1 proteins , 1994, Nature Genetics.

[39]  G. Myers Neurofibromatosis: A Handbook for Patients, Families, and Health Care Professionals , 1991 .